Ipilimumab: Attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma Journal Article


Authors: Peggs, K. S.; Quezada, S. A.
Article Title: Ipilimumab: Attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Abstract: Interference with the inhibitory immune regulatory checkpoints that act to constrain overly exuberant immune responses and help to maintain peripheral tolerance represents an exciting new paradigm in tumor immunotherapy. We review the study of Hodi and colleagues evaluating the role of blockade of one of these pathways (cytotoxic T-lymphocyte antigen-4) with a monoclonal antibody (ipilimumab, developed by Medarex, NJ, USA and Bristol-Myers Squibb, NY, USA) in patients with advanced melanoma who had failed prior treatments. The randomized Phase III study demonstrates superior overall survival in patients receiving ipilimumab, either alone or in combination with a gp100 peptide vaccine, compared with those receiving the vaccine alone. The results represent the first positive randomized clinical trial ever reported in patients with metastatic melanoma in terms of overall survival, the first showing a beneficial effect of a melanoma treatment in the second-line setting, and the first demonstration that blockade of an immune-inhibitory pathway can be an effective cancer therapeutic. © 2010 Expert Reviews Ltd.
Keywords: cancer survival; survival analysis; overall survival; clinical trial; advanced cancer; diarrhea; antineoplastic agents; note; glycoprotein gp 100; ipilimumab; ticilimumab; cancer immunotherapy; melanoma; metastasis; skin neoplasms; monoclonal antibody; antibodies, monoclonal; immunotherapy; cancer vaccine; cancer immunization; neoplasm metastasis; colitis; ctla-4; peptide vaccine; cytotoxic t lymphocyte antigen 4; endocrine disease; vaccine; hypopituitarism; vitiligo; cytotoxic t-lymphocyte antigen-4; phase iii
Journal Title: Expert Review of Anticancer Therapy
Volume: 10
Issue: 11
ISSN: 1473-7140
Publisher: Taylor & Francis Group  
Date Published: 2010-11-01
Start Page: 1697
End Page: 1701
Language: English
DOI: 10.1586/era.10.144
PUBMED: 21080797
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "CODEN: ERATB" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sergio A Quezada
    14 Quezada